Correlation Between Nkarta and Crispr Therapeutics
Can any of the company-specific risk be diversified away by investing in both Nkarta and Crispr Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Nkarta and Crispr Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Nkarta Inc and Crispr Therapeutics AG, you can compare the effects of market volatilities on Nkarta and Crispr Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Nkarta with a short position of Crispr Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Nkarta and Crispr Therapeutics.
Diversification Opportunities for Nkarta and Crispr Therapeutics
-0.35 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Nkarta and Crispr is -0.35. Overlapping area represents the amount of risk that can be diversified away by holding Nkarta Inc and Crispr Therapeutics AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Crispr Therapeutics and Nkarta is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Nkarta Inc are associated (or correlated) with Crispr Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Crispr Therapeutics has no effect on the direction of Nkarta i.e., Nkarta and Crispr Therapeutics go up and down completely randomly.
Pair Corralation between Nkarta and Crispr Therapeutics
Given the investment horizon of 90 days Nkarta Inc is expected to under-perform the Crispr Therapeutics. In addition to that, Nkarta is 1.41 times more volatile than Crispr Therapeutics AG. It trades about -0.08 of its total potential returns per unit of risk. Crispr Therapeutics AG is currently generating about 0.06 per unit of volatility. If you would invest 4,894 in Crispr Therapeutics AG on August 30, 2024 and sell it today you would earn a total of 190.00 from holding Crispr Therapeutics AG or generate 3.88% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Nkarta Inc vs. Crispr Therapeutics AG
Performance |
| Timeline |
| Nkarta Inc |
| Crispr Therapeutics |
Nkarta and Crispr Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Nkarta and Crispr Therapeutics
The main advantage of trading using opposite Nkarta and Crispr Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Nkarta position performs unexpectedly, Crispr Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crispr Therapeutics will offset losses from the drop in Crispr Therapeutics' long position.The idea behind Nkarta Inc and Crispr Therapeutics AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.| Crispr Therapeutics vs. Beam Therapeutics | Crispr Therapeutics vs. Editas Medicine | Crispr Therapeutics vs. Caribou Biosciences | Crispr Therapeutics vs. Verve Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Other Complementary Tools
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Stocks Directory Find actively traded stocks across global markets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |